Non-irritating concentrations recommended for skin testing by Europen network on Drug Allergy (ENDA)/European Academy of Allergy and Clinical Immunology (EAACI) [5] guidelines and AAIITO/SIAAIC [42] guidelines
Excipients | Excipients-containing substances | Substance name | Concentration | ENDA/EAACI guidelines | AAIITO/SIAAIC guidelines | ||
---|---|---|---|---|---|---|---|
SPT | I.D. | SPT | I.D. | ||||
PEG | PEG-containing vaccines | Comirnaty (PEG 2000) | 0.03 mg/0.03 mL | 1:1 | Starting at very low concentration | - | - |
Moderna (PEG 2000) | 0.1 mg/0.5 mL | 1:1 | Starting at very low concentration | - | - | ||
PEG-pure substances | PEG 300 | - | 1:1 | - | - | - | |
PEG 400 | 1:1 | ||||||
PEG 500 | 50% in water | ||||||
PEG 2000 | 1%, 10%, and 50% in water | ||||||
PEG 3000 | 10% in water | ||||||
PEG 4000 | 50% in water | ||||||
PEG 6000 | 50% in water | ||||||
PEG-containing drugs | Depo-Medrol (methylprednisolone acetate, PEG 3350) | 40 mg/mL | 1:1 | 1:100 and 1:10 | 1:1 | 1:1,000, 1:100, and 1:10 | |
Macrogol powder for oral solution (PEG 3350) | 170 mg/mL | 1:100, 1:10, and 1:1 | - | 1:100, 1:10, and 1:1 | - | ||
PEG-derivatives | Polaxamer 407 (PEG 4000) | - | 10% in water | - | - | - | |
PS80 | PS80-containing vaccines | AstraZeneca | 2.5 × 108 Inf.U/0.5 mL | 1:1 | - | - | - |
Johnson & Johnson | ≥ 8.92 log10 Inf.U/0.5 mL | 1:1 | - | - | - | ||
PS80-containing drugs | Kenacort (triamcinolone acetonide) | - | - | - | 1:1 | 1:100, 1:10, and 1:1 | |
Optive plus eye drops (carboxymethylcellulose) | - | - | - | 1:1 | 1:100 and 1:10 | ||
Tween 80 | - | - | 1%, 10%, and 20% in water | 0.1%, 1%, and 10% in saline | - | - |
Inf.U: infectious units; I.D.: intradermal. -: No data available
Note. Adapted with permission from “Allergies and COVID-19 vaccines: an ENDA/EAACI position paper,” by Barbaud A, Garvey LH, Arcolaci A, Brockow K, Mori F, Mayorga C, et al. Allergy. 2022;77:2292–312 (https://onlinelibrary.wiley.com/doi/10.1111/all.15241). © 2022 EAACI and John Wiley and Sons A/S.
FV and DGS: Investigation, Writing—original draft, Writing—review & editing. GC: Investigation, Writing—original draft, Conceptualization, Writing—review & editing. DP, FP, IZ, GL, MAL, GP, CMC, and VN: Investigation, Writing—original draft. DDB: Investigation, Writing—original draft, Validation, Supervision. EN: Conceptualization, Investigation, Writing—original draft, Validation, Supervision. All authors read and approved the submitted version.
The authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2024.